DexCom, Inc. vs iShares MSCI France ETF — how do they compare? DexCom, Inc. trades at $77.3 (market cap $28.06B), while iShares MSCI France ETF trades at $45.15. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | EWQ | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $48.35 |
52-Week Low | $54.84 | $41.43 |
Enterprise Value | $27.03B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →